Insight journal - Company

Lundbeck: Partnering activity 2005-2013

Posted on 07 January 2014

Tags: , , ,

Since 2005, Lundbeck, an international pharmaceutical company, announced over 50 partnering / licensing deals. Analysis of the partnering deals shows a strong emphasis on partnerships in psychiatric and neurological disorders.

Abstracted from: Partnering Deals and Alliances with Lundbeck

The number of partnering, collaborative R&D and licensing deals announced remained steadily year on year with a slight dip in 2012 alone.

The following figure shows the level of Lundbeck partnering deal announcements since 2005.

Figure 1: Lundbeck partnering deals 2005-2013

L1

 

Source: Current Agreements, 2012

Analysis of the partnering deals shows a strong emphasis on partnerships in psychiatric and neurological disorders. The specific therapeutic focus areas are Alzheimers, Parkinsons and schizophrenia.

The following table provides an overview of the partnering deals announced by Lunbeck based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Deals and Alliances with Lundbeck

Figure 2: Lundbeck partnering deals by therapy area 2005-2013

L2

 

Source: Current Agreements, 2013

Further analysis of these deals shows that Lundbeck has a preference for licensing deals, similar to many other top pharmaceutical or big pharma companies. Such partnering deals provide the right for Lundbeck to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments. In addition, Lunbeck has a tendency for collaborative R&D and development agreements.

The following table provides an overview of the partnering deals announced by Lundbeck based on deal type disclosed.

Figure 3: Lundbeck partnering deals by deal type 2005-2013

L3

 

Source: Current Agreements, 2013

When looking at stage of development at partnering deal signing, the most popular stage at signing is discovery stage with 17 deal announcements since 2005, closely followed preclinical and marketed stage deals. Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain diseases. Lundbeck, in common with many other top pharmaceutical companies, participates in marketed stage deals for the optimal commercialization of their product portfolio.

The following table provides an overview of the partnering deals announced by Lundbeck  based on stage of development at signature.

Figure 4: Lundbeck partnering by stage of development 2005-2013

L4

 

Source: Current Agreements, 2013

Lundbeck has signed over 50 partnering and licensing deals since 2005. The following provides two of the top deals by headline value signed by Lundbeck with the big pharma company Otsuka.

Figure 5: Top Lundbeck partnering deals by headline value 2005-2013

L5

Source: Current Agreements, 2013

Our report provides more detailed insight into the details of each deal. See: Partnering Deals and Alliances with Lundbeck

Lundbeck partnering at Current Agreements

View all partnering deals for Lundbeck: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Deals and Alliances with Lundbeck

More

Summary profile data for Lundbeck
Partnering interests for Lundbeck
M&A activity for Lundbeck

 

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Lundbeck

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

 

Available resources for deal coverage for Lundbeck

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Lundbeck company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

 

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply